What is the catalog number for IKBKG Antibody - middle region?

The catalog number for IKBKG Antibody - middle region is ARP30005_T100-25UL.

What sizes are available for IKBKG Antibody - middle region?

IKBKG Antibody - middle region is available in the following size(s): 25 µL.

Is IKBKG Antibody - middle region in stock?

IKBKG Antibody - middle region is currently made to order / not held in immediate stock. Contact us for lead time.

How many freeze-thaw cycles can this product tolerate?

We recommend aliquoting the product upon receipt to avoid repeated freeze-thaw cycles, which can reduce activity and stability. This is your responsibility once the product has been delivered.

Is antigen retrieval required for IHC with this antibody?

Recommended antigen retrieval methods, where applicable, are listed on the datasheet under the IHC protocol section.

What temperature does this product ship at?

Shipping temperature is chosen based on the product’s stability needs, ranging from ambient to dry ice, and is indicated on the product page. Any related shipping fee is shown clearly in your quotation.

IKBKG Antibody - middle region

Product Specifications

CAS Number

9007-83-4

Gene Name

Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma

Gene Aliases

IP, IP1, IP2, FIP3, IKKG, IPD2, NEMO, FIP-3, Fip3p, IMD33, AMCBX1, EDAID1, IKKAP1, ZC2HC9, IKK-gamma

Gene ID

8517

Swiss Prot

Q9Y6K9

Accession Number

NP_003630

Reactivity

Human, Mouse, Rat, Cow, Dog, Guinea Pig, Horse, Rabbit

Immunogen

The immunogen is a synthetic peptide directed towards the middle region of human IKBKG

Target

Familial incontinentia pigmenti (IP) is a genodermatosis that segregates as an X-linked dominant disorder and is usually lethal prenatally in males . In affected females it causes highly variable abnormalities of the skin, hair, nails, teeth, eyes, and central nervous system. The prominent skin signs occur in 4 classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation, and dermal scarring. Cells expressing the mutated X chromosome are eliminated selectively around the time of birth, so females with IP exhibit extremely skewed X-inactivation. Familial incontinentia pigmenti is caused by mutations in the NEMO gene and is here referred to as IP2, or 'classical' incontinentia pigmenti. Sporadic incontinentia pigmenti, the so-called IP1, which maps to Xp11, is categorized as hypomelanosis of Ito

Partner Proteins

CHUK; IKBKB; ATM; PIAS4; MALT1; TRIM13; BCL10; SUMO1; UBC; TRAF6; MTOR; RPTOR; RELA; NFKBIA; IKBKG; ARHGDIA; RHOA; CDC37; SRC; FYN; FKBP5; FGR; PPP4C; PPP2R1B; LYN; NMRAL1; USP7; ZC3H12A; IRAK1; USP10; RIPK1; SQSTM1; RNF31; PPP1CC; HDLBP; PPFIA1; PSMB8; K

Clonality

Polyclonal

Type

Polyclonal Antibody

Sequence

LGELQESQSRLEAATKECQALEGRARAASEQARQLESEREALQQQHSVQV

Applications

Purification

Protein A purified

Assay Protocol

Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Reconstitution & Storage Instructions Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Antibody Array (AA) Protocol